ID   A431 GR
AC   CVCL_E4DP
SY   A431-GR; A431_GR
DR   GEO; GSM270527
DR   GEO; GSM270528
DR   GEO; GSM270529
RX   PubMed=18568074;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Gene fusion; HGNC; HGNC:3236; EGFR + HGNC; HGNC:9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Skin, epidermis; UBERON=UBERON_0001003.
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0037 ! A-431
SX   Female
AG   85Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=18568074; DOI=10.1172/JCI34588; PMCID=PMC2430495;
RA   Guix M., Faber A.C., Wang S.-Z.E., Olivares M.G., Song Y., Qu S.,
RA   Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A.;
RT   "Acquired resistance to EGFR tyrosine kinase inhibitors in cancer
RT   cells is mediated by loss of IGF-binding proteins.";
RL   J. Clin. Invest. 118:2609-2619(2008).
//